ilorasertib: an antineoplastic agent and protein kinase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 46207586 |
| CHEMBL ID | 1980297 |
| SCHEMBL ID | 3381224 |
| MeSH ID | M0580588 |
| Synonym |
|---|
| SCHEMBL3381224 |
| KINOME_405 |
| bdbm50381716 |
| us8722890, 2 |
| us8722890, 1 |
| a-968660.0 |
| abt-348 |
| a-968660 |
| CHEMBL1980297 |
| abbott-968660 |
| ilorasertib |
| 6l5d03d975 , |
| abbott-969660 |
| urea, n-(4-(4-amino-7-(1-(2-hydroxyethyl)-1h-pyrazol-4-yl)thieno(3,2-c)pyridin-3-yl)phenyl)-n'-(3-fluorophenyl)- |
| unii-6l5d03d975 |
| 1-(4-(4-amino-7-(1-(2-hydroxyethyl)-1h-pyrazol-4-yl)thieno(3,2-c)pyridin-3-yl)phenyl)-3-(3-fluorophenyl)urea |
| 1227939-82-3 |
| ilorasertib [usan:inn] |
| ilorasertib (usan) |
| D10423 |
| ilorasertib [who-dd] |
| ilorasertib [usan] |
| ilorasertib [inn] |
| n-(4-(4-amino-7-(1-(2-hydroxyethyl)-1h-pyrazol-4-yl)thieno(3,2-c)pyridin-3-yl(phenyl)-n'-(3-fluorophenyl)urea |
| WPHKIQPVPYJNAX-UHFFFAOYSA-N |
| n-(4-{4-amino-7-[1-(2-hydroxyethyl)-1h-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-n'-(3-fluorophenyl)urea |
| DTXSID10153718 |
| CS-6804 |
| HY-16018 |
| 1-(4-(4-amino-7-(1-(2-hydroxyethyl)-1h-pyrazol-4-yl)thieno[3,2-c]pyridin-3-yl)phenyl)-3-(3-fluorophenyl)urea |
| DB11694 |
| abt 348 |
| abt348 |
| 1-[4-[4-amino-7-[1-(2-hydroxyethyl)pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl]phenyl]-3-(3-fluorophenyl)urea |
| gtpl9914 |
| BCP07256 |
| E77316 |
| SB16853 |
| Q27265085 |
| abt-348abt-348 |
| A905680 |
| nsc765889 |
| nsc-765889 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacodynamic markers suggested that ilorasertib engaged VEGFR2 and Aurora B kinase, with the VEGFR2 effects reached at lower doses and exposures than Aurora inhibition effects." | ( Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. Ansell, P; Donawho, C; Falchook, G; Hoening, E; Hong, D; Janisch, L; Karovic, S; Kurzrock, R; Lian, GK; Maitland, ML; McKee, M; Munasinghe, W; Nguyen, L; Palma, J; Piha-Paul, S; Ratain, MJ; Wong, S, 2018) | 0.7 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Aurora kinase A | Homo sapiens (human) | IC50 (µMol) | 0.0660 | 0.0000 | 0.4620 | 8.6000 | AID1676610; AID659338 |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0001 | 0.3722 | 10.0000 | AID659350 |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | IC50 (µMol) | 0.0120 | 0.0001 | 0.7128 | 10.0000 | AID659343 |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | IC50 (µMol) | 0.0030 | 0.0002 | 1.3173 | 10.0000 | AID659342 |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | IC50 (µMol) | 0.1100 | 0.0002 | 1.6789 | 8.6800 | AID659345 |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | IC50 (µMol) | 0.0160 | 0.0006 | 0.5676 | 5.5450 | AID659341 |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | Ki | 0.0032 | 0.0032 | 0.0066 | 0.0100 | AID673706 |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | IC50 (µMol) | 0.0070 | 0.0001 | 0.3484 | 3.5970 | AID659344 |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | IC50 (µMol) | 0.5390 | 0.0003 | 0.4308 | 8.0000 | AID659349 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0001 | 1.7536 | 10.0000 | AID659312 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | IC50 (µMol) | 0.0030 | 0.0006 | 0.8007 | 8.5000 | AID659340 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | IC50 (µMol) | 0.1880 | 0.0002 | 0.9420 | 10.0000 | AID659346 |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | Ki | 0.0008 | 0.0008 | 0.0054 | 0.0100 | AID673707 |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | IC50 (µMol) | 0.0320 | 0.0001 | 0.2914 | 7.0000 | AID659339 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 0.0028 | 0.0000 | 0.4830 | 8.8000 | AID659306; AID659355; AID677867; AID677869 |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0010 | 1.2249 | 9.1000 | AID659353 |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0010 | 0.6236 | 8.0000 | AID659352 |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0001 | 0.4193 | 7.9200 | AID659351 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 (µMol) | 1.0000 | 0.0009 | 1.9014 | 10.0000 | AID659321 |
| Rho-associated protein kinase 1 | Homo sapiens (human) | IC50 (µMol) | 0.4560 | 0.0004 | 0.8549 | 10.0000 | AID659348 |
| Aurora kinase B | Homo sapiens (human) | IC50 (µMol) | 0.0070 | 0.0003 | 0.9634 | 9.8000 | AID1676641; AID659307; AID659356; AID677868 |
| ALK tyrosine kinase receptor | Homo sapiens (human) | IC50 (µMol) | 0.3630 | 0.0001 | 0.3107 | 10.0000 | AID659347 |
| Aurora kinase C | Homo sapiens (human) | IC50 (µMol) | 0.0070 | 0.0010 | 0.4137 | 8.6000 | AID1676612 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Aurora kinase B | Homo sapiens (human) | EC15 (µMol) | 0.0120 | 0.0120 | 0.0120 | 0.0120 | AID659309 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID493040 | Navigating the Kinome | 2011 | Nature chemical biology, Apr, Volume: 7, Issue:4 | Navigating the kinome. |
| AID659317 | Clearance in CD1 (ICR) mouse at 3 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659312 | Inhibition of CYP3A4 | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659335 | Half life in rat | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID673706 | Inhibition of CSF1R | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5 | Targeted kinase selectivity from kinase profiling data. |
| AID659326 | Protein binding in rat | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659354 | Time dependent inhibition of CYP3A4 up to 10 uM | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659336 | Half life in mouse | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659330 | Plasma clearance in mouse | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659342 | Inhibition of LCK by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659352 | Inhibition of CDK9 by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659328 | Protein binding in dog | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID677870 | Cell cycle arrest in human NCI-H1299 cells assessed as induction of polyploidy after 48 hrs by Hoechst staining-based fluorescence microscopic analysis | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases. |
| AID677868 | Inhibition of Aurora B kinase by HTRF analysis in presence of 1 mM ATP | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases. |
| AID659325 | Aqueous solubility of the compound | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659327 | Protein binding in mouse | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659322 | Cardiotoxicity in dog assessed as QT prolongation time at 32.1 uM plasma concentration | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID677867 | Inhibition of KDR by HTRF analysis in presence of 1 mM ATP | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases. |
| AID659353 | Inhibition of GSK3alpha by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659319 | Oral bioavailability in CD1 (ICR) mouse at 10 mg/kg | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659314 | Inhibition of CYP3A4 up to 10 uM | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659316 | Volume of distribution in CD1 (ICR) mouse at 3 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659309 | Inhibition of Aurora B in human NCI-H1229 cells assessed as induction of polyploidy formation after 48 hrs by Hoechst staining-based fluorescence analysis | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659324 | Lipophilicity, log D of the compound at pH 7 | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659306 | Inhibition of KDR using 1 mM ATP by HTRF assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659333 | Volume of distribution at steady state in mouse | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659338 | Inhibition of Aurora A by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659339 | Inhibition of Flt1 by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659329 | Plasma clearance in rat | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659349 | Inhibition of IGF1R by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659345 | Inhibition of FYN by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659310 | In vivo inhibition of KDR in po dosed mouse assessed as estradiol-induced uterine edema | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659355 | Inhibition of KDR by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659315 | Half life in CD1 (ICR) mouse at 3 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659334 | Volume of distribution at steady state in dog | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID1676612 | Inhibition of AuroraC (unknown origin) | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23 | The synthesis and anti-tumour properties of novel 4-substituted phthalazinones as Aurora B kinase inhibitors. |
| AID659348 | Inhibition of ROCK1 by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659346 | Inhibition of FGFR1 by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID677869 | Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases. |
| AID659343 | Inhibition of ABL by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659340 | Inhibition of PDGFRbeta by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659350 | Inhibition of JAK2 by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659331 | Plasma clearance in dog | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659337 | Half life in dog | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659332 | Volume of distribution at steady state in rat | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659356 | Inhibition of Aurora B by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID673707 | Inhibition of PDGFRA | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5 | Targeted kinase selectivity from kinase profiling data. |
| AID659344 | Inhibition of RET by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659318 | AUC in CD1 (ICR) mouse at 10 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659347 | Inhibition of ALK by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659323 | Cardiotoxicity in dog assessed as QT prolongation time at 117 uM plasma concentration | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID1676610 | Inhibition of AuroraA (unknown origin) | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23 | The synthesis and anti-tumour properties of novel 4-substituted phthalazinones as Aurora B kinase inhibitors. |
| AID659307 | Inhibition of Aurora B using 1 mM ATP by HTRF assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659341 | Inhibition of CSF1R by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659351 | Inhibition of JAK3 by TR-FRET assay | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID659321 | Inhibition of human Erg by patch clamp assay in absence of plasma protein | 2012 | Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9 | Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. |
| AID1676641 | Inhibition of AuroraB (unknown origin) | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23 | The synthesis and anti-tumour properties of novel 4-substituted phthalazinones as Aurora B kinase inhibitors. |
| AID1345506 | Human kinase insert domain receptor (Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family) | 2012 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 343, Issue:3 | Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. |
| AID1345646 | Human aurora kinase C (Aurora kinase (Aur) family) | 2012 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 343, Issue:3 | Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. |
| AID1345688 | Human aurora kinase B (Aurora kinase (Aur) family) | 2012 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 343, Issue:3 | Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. |
| AID1345668 | Human aurora kinase A (Aurora kinase (Aur) family) | 2012 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 343, Issue:3 | Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. |
| AID1345555 | Human KIT proto-oncogene receptor tyrosine kinase (Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family) | 2012 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 343, Issue:3 | Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. |
| AID1345563 | Human platelet derived growth factor receptor alpha (Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family) | 2012 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 343, Issue:3 | Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. |
| AID1345520 | Human fms related tyrosine kinase 4 (Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family) | 2012 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 343, Issue:3 | Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. |
| AID1345503 | Human fms related tyrosine kinase 3 (Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family) | 2012 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 343, Issue:3 | Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. |
| AID1345548 | Human fms related tyrosine kinase 1 (Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family) | 2012 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 343, Issue:3 | Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. |
| AID1345590 | Human platelet derived growth factor receptor beta (Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family) | 2012 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 343, Issue:3 | Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. |
| AID1345508 | Human colony stimulating factor 1 receptor (Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family) | 2012 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 343, Issue:3 | Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.21) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (22.22%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (77.78%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||